Details

Acute Heart Failure


Acute Heart Failure

Putting the Puzzle of Pathophysiology and Evidence Together in Daily Practice
2nd ed. 2017

von: Wolfgang Krüger

117,69 €

Verlag: Springer
Format: PDF
Veröffentl.: 18.07.2017
ISBN/EAN: 9783319549736
Sprache: englisch

Dieses eBook enthält ein Wasserzeichen.

Beschreibungen

<p>Acute heart failure is a potentially life threatening situation where correct, rapid therapy can save lives. Information from the latest research and studies has been used to update this text to bring the latest understanding of the pathophysiology together with a practical guide to diagnosis and management using an evidenced based approach.</p><p>Since the first edition of Acute Heart Failure, this research has brought to light three important issues to be integrated into a second edition. First, the so-called “vascular heart failure” has been identified as a common and decisive mechanism provoking acute heart failure due to the coupling and interaction between the heart (right and left heart) and the large vessel systems (aorta and pulmonary artery). Second, the interaction and cross-talk between heart and kidneys, the so-called ‘cardiorenal syndrome’ has been identified as another feature of acute heart failure syndromes. Third, we have new knowledge and updated points of views about the development of pulmonary hypertension in patients suffering from heart failure, the group 2 of the classification system of pulmonary hypertension. These are all covered in this second edition.</p><p>This revision to a seminal text is a valuable addition to any practitioner who treats patients with acute heart failure and wants a deeper understanding of the condition.<br/></p>
Foreword<p></p> <p> </p> <p>1         <b>Cardiac physiology of acute heart failure syndromes</b></p> <p>    1.1 Cardiac performance</p> <p>    1.2 The fundamental equation of the circulation </p> <p>    1.3 Preload </p> <p>           a) Definition </p> <p>           b) Frank–Starling mechanism </p> <p>           c) Venous return and CVP in daily practice </p> <p>     1.4 Haemodynamic monitoring</p> <p>           a) Assessment and monitoring of fluid status</p> <p>           b) Prediction of fluid responsiveness</p> <p>                i) Pressure measurements </p> <p>                ii) Volumetric measurements </p> <p>                iii) Dynamic parameters </p> <p>                iv) Fluid challenge</p> <p>                v) PiCCO-monitoring </p> <p>                vi) Echocardiography</p> <p>           c) Arterial blood pressure </p> <p>                 i) BP and autoregulation </p> <p>                 ii) Assessment of tissue perfusion </p> 1.5 Afterload <p></p> <p>           a) Definition</p> <p>           b) Vascular properties, effective arterial elastance, wall stress and the law of LaPlace</p> <p>           c) Afterload mismatch and acute heart failure syndromes </p> <p>1.6 Contractility </p> <p>           a) Definition </p>            b) Ventricular elastance and other measurements and indicators of contractility        <p></p> <p>           c) Inotropic medications </p> <p>1.7 Heart rate and contractility  </p> <p>1.8 Diastolic ventricular interaction/interdependance (DVI)  </p> <p>       a) Definition  </p> <p>       b) Septum and trans-septal pressure  </p> <p>       c) Pericardium  </p> <p>       d) Pulmonary hypertension and the risk of DVI                  </p> <p>       e) Acutely exacerbated chronic congestive (left-sided or biventricular) HF  </p> <p>       f) Conclusions </p> <p>1.9 Ventriculo-arterial coupling </p> <p>       a) Definition </p> <p>       b) Arterial elastance </p> <p>       c) Ventricular elastance</p> <p>       e) Deranged coupling</p> <p>1.10 Myocardial and chamber stiffness</p> <p>1.11 Evaluation and assessment of cardiac performance </p> <p>1.12 Summary </p> <p>      a) Key physiology</p> <p>      b) Afterload </p> <p>      c) Systolic function</p> <p>      d) Volume status</p> <p>      e) Ventriculo-arterial coupling </p> <p>      f) Diastolic ventricular interaction</p> <p>      g) Myocardial and chamber stiffness</p> <p>      h) Cardiac power output / index</p> <p>      i) Echocardiography</p> <p> </p> <p> </p> <p>2             <b>Acute heart failure syndromes</b> </p> <p>2.1 Definition </p> <p>2.2 Classification of acute heart failure syndromes (AHFS)</p> <p>2.3 Etiology and epidemiology</p> <p>2.4 Pathophysiology</p> <p>      a) General pathophysiological remarks </p> <p>      b) Special pathophysiological issues</p> <p>          i)   LVEDP and congestion</p> <p>          ii)  Neurohormonal systems, endothelial dysfunction and inflammation</p> <p>          iii) Vascular properties, AV-coupling, afterload mismatch and Cotter`s dual pathway concept </p> <p>          iv) Fluid redistribution, splanchnic veins and the venocentric input</p> <p>          v)  Fluid accumulation, venous congestion and the link between cardiac and vascular pathway</p> <p>          vi) (Self)-amplification and vicious cycles</p> <p>       c)  Summary </p> <p>2.5 Diagnosis, symptoms, presentation, important clinical and prognostic data  </p> <p>       a) Typical symptoms and diagnosis</p>        b) Prognostic indicators  <p></p> <p>       c) Initial clinical assessment, diagnostic measures and considerations</p> <p>           i)   Hemodynamic profiles on admission</p> <p>           ii)  Identification of precipitants  </p> <p>           iii) Other diagnostic measures</p> <p>2.6 Therapy </p> <p>     a) Therapeutic principles and goals</p>      b) Initial therapeutic approach <p></p> <p>         i)  Treatment of underlying  diseases </p> <p>         ii)  Common basic measures</p> <p>         iii)  Typical and specific measures</p> <p>-          Diuretics and ultrafiltration</p> -          Vasodilators <p></p> <p>-          Inotropic drugs</p> <p>          iv)  Essential, permanent medication in the acute phase</p> <p>          v)   Arrhythmias and heart failure</p> <p>          vi)  Continuous  positive airway pressure (CPAP) and other non-invasive positive pressure  </p> <p>                  ventilatory support (NIPPV)  </p> <p>           vii) Anticoagulation </p> <p>2.7 Valvular heart disease presenting as heart failure</p> <p>       a) Mitral regurgitation </p> <p>       b) Mitral stenosis </p> <p>       c) Aortic regurgitation </p> <p>       d) Aortic stenosis </p> <p>2.8 Summary </p> <p> </p> <p>3         <b>Cardiogenic shock</b> </p> <p>3.1 Definition </p> <p>3.2 Epidemiology</p> <p>3.3 Etiology </p> <p>3.4 Pathophysiological aspects and special pathobiological features</p> <p>       a) Classical pathophysiology and new cardiogenic shock paradigm </p> <p>       b) The role and impact of hypotension in cardiogenic </p> <p>       c) Myocardial ischemia and LV- compliance </p> <p>       d) The right ventricle and cardiogenic shock</p> <p>       e) Other acute causes of a substantial impairment in contractility </p> <p>3.5 Clinical features and diagnostic remarks</p> <p>       a) Hypoperfusion </p> <p>       b) Right ventricular infarction </p> <p>       c) The LVEDP in cardiogenic shock</p> <p>       d) Differential diagnosis of cardiogenic shock </p> <p>3.6 Therapy </p> <p>       a) Main therapeutic strategies</p> <p>       b) Adjunctive treatment</p> <p>           i)    Re-establishing and maintaining appropriate coronary and systemic perfusion</p> <p>           ii)   Fluid administration</p> <p>           iii)   Vasopressor administration</p> <p>           iv)   Inotropic medication </p> <p>           v)   Intra-aortic balloon counter pulsation (IABP)</p> <p> </p> <p>           vi)  Renal function</p> <p> </p> <p>           vii) Compensation of acidosis</p> <p> </p> <p>           viii) Anticoagulation therapy  </p> <p> </p> <p>3.7 Summary </p> <p> </p> <p>4      <b>Acute right heart failure</b> </p> <p>4.1 Definitions </p> <p>4.2 Epidemiology and etiology </p> <p>4.3 Physiological and pathophysiological aspects </p> <p>      a) General physiology and pathophysiology</p> <p>      b) Special pathophysiological issues</p> <p>            i)     Diastolic ventricular interactions </p> <p>            ii)    The role of the pericardium in diastolic-ventricular interaction</p> <p>            iii)   Auto-aggravation  </p> <p>            iv)   Series effect </p> <p>             v)  Pulmonary hypertension and ischemia </p> <p>            vi)  The interventricular septum and the apex</p> <p>            vii) The left ventricle</p> <p>            viii) Mechanical ventilation </p> <p>4.4 Diagnostic aspects </p> <p>       a)  Clinical features </p> <p>       b)  Serum biomarkers </p> <p>       c)  Electrocardiography </p> <p>       d)  Echocardiography</p> <p>       e)  Invasive hemodynamic assessments</p> <p>4.5 Therapy </p> <p>      a) Specific measures </p> <p>      b) Adjunctive therapy </p> <p>          i)   Fluid management and optimization of preload, diuretics </p> <p>          ii)   Vasopressors: Treatment and avoidance of ischemia</p> <p>          iii)  Critical RV-afterload reduction</p> <p>          iv)   Improvement of RV systolic function / contractility </p> <p>          v)    Intra-aortic balloon pump </p> <p>          vi)   Hypercapnia and acidosis </p> <p>          vii)  Oxygen therapy </p> <p>          viii)  AV sequential stimulation</p> <p>           ix)   Mechanical ventilation </p> <p>           x)    Anticoagulation </p> <p>           xi)   Digoxin </p> <p>     c) Therapeutic conclusions </p> <p>4.6   Summary </p> <p>     a) Pathophysiological and clinical issues </p> <p>     b) Overview of treatment options, figure by Naeije and and Manes </p> <p> </p> <p>5      <b>Heart failure with normal left ventricular ejection fraction (HFNEF)</b> </p> <p>5.1 Definition and general remarks</p> <p>5.2 Epidemiology and etiology </p> <p>5.3 Etiopathogenesis and basic pathophysiological issues and considerations<b> </b></p> <p>5.4  Special pathophysiology  </p> <p>        a)   The pressure-volume relation and the filling pressure (LVEDP) in HFpEF</p> <p>        b)   Pathomechanisms  </p> <p>                i)     Diastolic dysfunction</p> <p>                ii)    Vascular stiffening and av-coupling</p>     iii)   Systolic function and cardiac reserve<p></p> <p> </p> <p>    iv)   Pulmonary hypertension and RV dysfunction, DVI</p> <p> </p> <p>    v)    Ventricular dys-synchrony</p>  <p></p> <p>    vi)   Left atrial dysfunction</p> <p> </p> <p>    vii)  Peripheral factors    </p> <p> </p> 5.5   Diagnosis and clinical issues<p></p> <p> </p> <p>a)       Symptoms and signs of heart failure</p> <p> </p> b)       Ejection fraction<p></p> <p> </p> <p>c)       Diastolic dysfunction, structural changes and bio-markers</p> <p> </p> i)        Natriuretic peptides<p></p> <p> </p> <p>ii)    Functional and structural alterations</p> <p> </p> <p>iii)   E/e`ratio</p> <p> </p> <p>iv)   Inconclusive E/e`ratio - surrogate markers</p> <p> </p> <p>v)    Invasively derived parameters   </p> <p> </p> vi)   Diastolic stress test<p></p> <p> </p> <p>5.6     Therapy </p> <p> </p> <p>6   <b>Pulmonary hypertension (PH) in left heart disease (LHD - PH)</b></p> <p>1.          Definition</p> 2.          Classification of pulmonary hypertension<p></p> <p>3.           Epidemiology of PH due to LHD</p> <p>4.           Pathophysiology</p> <p>5.           Clinical issues and diagnosis</p> <p>6.           Therapeutic considerations</p>  <p></p> <p>7   <b>Cardiorenal syndrome  (CRS)</b></p> <p>1.       Definition</p> <p>2.       Epidemiology and prognostic issues </p><p>3.       Clinical issues and diagnosis</p> <p>4.       Pathophysiology</p> <p>5.       Management</p> <p>a)      Diuretics</p> <p>b)      Blood pressure /renal perfusion pressure</p> <p>c)       Further measures</p> <p> </p> <p> </p> <p>Index </p> <p>Abbreviations </p>
<div><div><p>Dr.  Wolfgang Kruger is a physician trained and specialized in general internal medicine, cardiology and intensive care medicine, with international certification. He has worked as a consultant intensivist and cardiologist throughout Europe, with special interests in acute heart failure and circulatory disorders of critically ill patients. Currently he is working as senior consultant at the Medical University Department of the Cantonal Hospital in Aarau, Switzerland, where he holds teaching responsibilities. His attempt to incorporate the newest research into everyday evidence-based medicine led him to write a textbook on this topic.</p></div></div><div></div><div></div>
<p>This new and revised edition of this definitive text on this topic provides extensive comprehensive guidance on the management of acute heart failure, the potentially life-threatening situation where correct, rapid therapy can save lives. It presents the latest research and studies and combines this latest understanding of the pathophysiology with a practical guide to diagnosis and management using a thoroughly evidence-based approach.</p> <p>Always keeping the underlying pathophysiology at the forefront of the discussion, <i>Acute Heart Failure</i> encourages readers to understand the underlying pathogenesis and pathobiology of the acute situation and how to direct management in order to address the abnormal physiology.  This revision to a seminal text includes new and substantial insights gained over the last few years and represents a valuable source to any practitioner who treats patients with acute heart failure who wants a comprehensive and deeper understanding of the condition, as well as expanding their capacities for an individualized approach to each patient.</p><p></p> <p></p><p></p>
<p>Evidence-based review of the pathophysiology, diagnosis, and therapy of acute heart failure syndromes</p><p>Designed for easy use in everyday clinical practice, an introduction into the topic</p><p>Designed to satisfy the need of Acute Medicine/the Heart Team concept</p><p>Contains extensive references, allowing the reader to easily refer to the original experimental studies</p>

Diese Produkte könnten Sie auch interessieren:

BOA - Einfach alles!
BOA - Einfach alles!
von: Michael Preuss
EPUB ebook
39,99 €
Samoe glavnoe o zhenskom zdorove. Voprosy nizhe poyasa
Samoe glavnoe o zhenskom zdorove. Voprosy nizhe poyasa
von: Elizaveta Grebeshkova, Olga Sedova
ZIP ebook
9,99 €